QUALITY-ADJUSTED TIME WITHOUT SYMPTOMS OF DISEASE OR TOXICITY IN PATIENTS WITH PRIMARY ADVANCED OR RECURRENT ENDOMETRIAL CANCER TREATED WITH DOSTARLIMAB PLUS CARBOPLATIN-PACLITAXEL VERSUS CARBOPLATIN-PACLITAXEL IN THE ENGOT-EN6/GOG-3031/RUBY TRIAL

Dana Chase, Line Bjorge,Robert L. Coleman, Oleksandr Zub, Eirwen Miller, Roberto Angioli, Cara Mathews,Lars C. Hanker,Michael G. Teneriello, Anna Reyners,Matthew Powell,Lucy Gilbert,Noelle Cloven, Sarah Gill,Bradley J. Monk,Bhavana Pothuri,Jamie Garside, Odette Allonby,Carolyn Mccourt,Mansoor Raza Mirza

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER（2023）

引用 0|浏览0

暂无评分

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要